N
Nucleus Genomics
Biotech & Life Sciences · New York City, United States · Founded 2021
Offers an all-in-one DNA health test, combining whole-genome sequencing with lifestyle factors to deliver the comprehensive insights into health and well-being MoreLess
Nucleus Genomics provides DNA testing and analysis services. The company offers an all-in-one DNA test that provides insights into a person's genetic makeup.
One of the company's key offerings is Nucleus Embryo, a genetic optimization software designed to assist parents undergoing in-vitro fertilization (IVF). This software helps in the selection of embryos with the most desirable genetic traits.
In addition to its consumer-facing products, Nucleus Genomics also provides a free gene variant discovery tool called GenVue Discovery. This tool is compatible with various data sources and allows users to explore their genetic data in more detail.
The company operates in the direct-to-consumer genetic testing market, serving individuals and couples who are interested in learning more about their genetic predispositions and, in the case of IVF patients, optimizing their chances of a successful pregnancy.
Nucleus Genomics places a strong emphasis on data privacy and security, as evidenced by its detailed privacy policy and HIPAA notice. The company is committed to protecting the personal and health information of its users.
Keywords: DNA testing, genetic analysis, embryo selection, IVF, gene variant discovery, direct-to-consumer genetics, bioinformatics, genetic screening, personalized medicine, reproductive health
Company overview
Nucleus Genomics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- New York City, United States
- Employees
- 43
- Open positions
- None listed
- Dealroom signal
- 82.2
- Investment activity
- 1 companies · latest Jan 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Nucleus Genomics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2025 | $14M | $56M | Amanda Bradford · Asylum VC · Founders Fund · Neo vc | ↗ |
| SEED✓Equity / VC | Jul 2022 | $14M | $56M | Adrian Aoun · Packy McCormick · Founders Fund · Austen Allred | ↗ |
| SEED✓Equity / VC | Dec 2021 | $3.5M | $14M | Edward Lando · Adrian Aoun · Quiet Capital · Brandon White | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 44 |
| 2025 | 39 |
| 2024 | 26 |
| 2023 | 22 |
| 2022 | 12 |
Growth signals
Nucleus Genomics website traffic
Latest recorded traffic for Nucleus Genomics is 99K monthly website visits, down 1% over the last three months. Nucleus Genomics's team grew 10.3% over the past year.
Comparisons
Nucleus Genomics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Blueprint GeneticsUses Next Generation Sequencing (NGS) to perform diagnostics on genetic diseases |
Espoo, Finland | Operational | 220 | $36M | $62M |
 Nucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine |
Oxford, United Kingdom | Operational | |||
 AnnoroadA leading developer and marketer on genomic innovation technologies for research and clinical market |
Dongcheng District, China | Operational | |||
 BiomodalSimultaneous genetic and epigenetic sequencing from single samples |
Cambridge, United Kingdom | Operational | |||
 BGIDNA sequencing service provider part of BGI Group |
Shenzhen, China | Operational | |||
 Probably GeneticProbably Genetic helps rare genetic disease patients get diagnosed |
San Francisco, United States | Operational | |||
 GeneCast BiotechnologyIt is a Beijing cancer diagnosis company |
Haidian, China | Operational | |||
 23MofangGenetics testing and analyzing Startup Based In China |
Chengdu, China | Operational |
Capital deployed
Nucleus Genomics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Nucleus Genomics's talent
Source: Dealroom Talent Intelligence.
Investors
34 investors on Nucleus Genomics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Nucleus Genomics has talent and traffic
team presence
In the news
Latest news about Nucleus Genomics
Recent press, funding announcements, and product moves mentioning Nucleus Genomics — open to read from the original sources.
Market sentiment
What the market is saying about Nucleus Genomics
An AI-synthesized read of the highest-engagement posts about Nucleus Genomics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nucleus Genomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.